Zumio(TM) Now Available in Europe
Exclusive Partnership Agreement Signed with Eropartner Distribution
Ottawa, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Zumio Inc. proudly announces it has partnered exclusively with Eropartner Distribution for distribution across all 28 EU member countries. Winner of the Best New Product at ADULTEX 2017, Zumio is the world's only clitoral stimulator based on the proven circular fingertip motion. Zumio's patented SpiroTIP(TM) and motor clutch drive system allows users to dynamically go from high speed and intensity down to a low speed and intensity, without having to touch a control, to instinctively and more naturally, adjust the stimulation to suit their needs.
"Traditional vibrators generate excess energy and shake everything they touch often creating sensory overload and a numbing effect," said Steve Traplin, Chief Revenue Officer at Zumio. " Our non-vibrating technology makes Zumio more comfortable to hold and the small TIP and dynamic control makes the energy delivered to the clitoral nerve more selective - delivering a broad spectrum of pleasurable experiences."
To learn more about Zumio, please visit our team in the Eropartner Booth during EroFame 2017 in Hannover, Germany from October 11 - 13, 2017.
"We are so extremely excited about our partnership with Zumio. After our team has tested the product we were strongly convinced right away. Now we are starting to get many positive feedback about this beautiful and revolutionary product from testers, bloggers and happy customers," said Chris Bakker, CEO of Eropartner. "We strongly believe Zumio is be a winner and that it will become one of best products available in the market!"
About Zumio(TM) Inc.
Zumio transforms women's desires and ideas into innovative products and experiences. Our flagship clitoral stimulation product, Zumio, was conceived, designed and perfected by women. The unique, patented SpiroTIP(TM) motion was inspired by the natural movement women have used to pleasure themselves throughout the ages. Zumio can deliver a fast, intense orgasm, multiple orgasms, or hours of delicious exploration for a unique experience each time. Zumio was created by the design and engineering team that helped Standard Innovation develop the world's leading We-Vibe® pleasure product, and Joylux Inc. to develop vSculpt(TM), the world's first vaginal rejuvenation product, for the sexual health and wellness industry. For more information, please visit www.myzumio.com
Zumio is available for purchase from a growing list of distributors and retailers in Europe, Australia, New Zealand, USA, Canada and China.
About EroPartner Distribution
Eropartner Distribution was created to support retail businesses selling products that enhance people's intimate relationships and encourage informed sexual exploration. We offer state of the art order processing, drop shipping services, international and nationwide shipping. We can handle orders of all sizes from large containers to one or two items as needed. We pride ourselves on outstanding customer service! At Eropartner Distribution we are committed to providing sensational service, outstanding product selection and unsurpassed delivery to and for our customers.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d6e2dc70-08fb-499a-8155-a74a7b9c9750
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d212951a-186b-4715-acf8-d426b3005136
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zumio Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Banque Fédérative du Credit Mutuel: Post Stabilisation Notice22.1.2018 15:10 | Pressmeddelande
PARIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Banque Fédérative du Credit Mutuel Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer: Banque Fédérative du Credit Mutuel Guarantor (if any): na Aggregate nominal amount: GBP 450,000,000 Description: 1.375% due Dec 2021 Offer price: 99.872 Stabilising Managers: HSBC & Goldman Sachs This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS The company news service from the London Stock Exchange Contacts: RNS Customer Services 0044-207797-4400 email@example.com http://www.rns.com This announ
FDA Grants Diazyme 510(k) Clearance to Market Its New EZ Vitamin D Assay for Clinical Chemistry Analyzers22.1.2018 15:00 | Pressmeddelande
SAN DIEGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Diazyme Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(K) clearance to market its EZ Vitamin D assay for Clinical Chemistry Analyzers. Diazyme's two reagent EZ Vitamin D assay provides the only fully automated two reagent Vitamin D test for use on validated clinical chemistry analyzers. "Diazyme's EZ Vitamin D assay is a universal fully automated Vitamin D test that is specifically designed for use on clinical chemistry analyzers. This liquid stable, ready-to-use two reagent system measures total 25-hydroxy Vitamin D (25-OH Vitamin D2 + 25-OH Vitamin D3) levels. This assay enables clinical laboratories of almost any size to run Vitamin D test in house without the need for expensive specialized instrumentation. With no sample pre-treatment or pre-dilution steps required, this high-throughput liquid stable assay provides precise test results, is user friendly, cost effective and has excellen
Fura Completes Acquisition of Colombian Emerald Mine, Coscuez22.1.2018 13:00 | Pressmeddelande
TORONTO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Fura Gems Inc. (TSXV:FURA) is pleased to announce that it has completed its acquisition of 76% of the issued and outstanding shares of Esmeracol S.A. ("Esmeracol"), which owns a 100% interest in mining licence no. 122 - 95M (the "Coscuez Licence"). Dev Shetty, President & CEO of Fura, commented: "Fura has achieved one more important milestone by adding the iconic Colombian emerald mine, Coscuez, to its portfolio. With this acquisition, Fura now has two important silos in its portfolio, Colombian emeralds and Mozambican rubies. Fura will now work towards modernisation of the Coscuez emerald mine and deployment of the best health and safety standards for its employees while keeping the environmental impact minimal. Fura will also closely work with the local community and relevant authorities to promote the social-economic development in the region. We would like to thank our local partner and also the entire team on the ground in the Colombia fo
Agency for the Cooperation of Energy Regulators (ACER) continues to use Nasdaq's SMARTS for Pan-European Market Monitoring of EU Wholesale Energy Markets22.1.2018 12:30 | Pressmeddelande
NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- The Agency for the Cooperation of Energy Regulators (ACER) has officially extended its contract with Nasdaq (Nasdaq:NDAQ) to continue to leverage Nasdaq's SMARTS Market Surveillance technology to detect insider trading and market manipulation across the European Union's wholesale energy markets by digesting and analyzing massive volumes of data from hundreds of power producers, exchanges, operators, and brokers across 28 member states. The new agreement contract extension will continue to allow national regulatory authorities to share data, technology, and expertise, with the aim of creating a cooperative regulatory infrastructure. Under the contract, SMARTS technology will continue being leveraged to monitor the European wholesale gas and electricity markets, covering both spot trading and derivative markets across Europe in accordance with the obligations under the REMIT legislation. Further, the surveillance technology will support ACER's
Bell Canada Reaches Milestone in Network 3.0 Vision with Open Network Automation Platform (ONAP) and Strategic Partnership with Amdocs22.1.2018 12:00 | Pressmeddelande
Bell's leadership in bringing open source ONAP into production enables innovative new offerings to customers faster and at lower cost ST. LOUIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Amdocs (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today announced that Bell, Canada's largest communications company, has successfully implemented the first network automation use case in production leveraging the Linux Foundation's Open Network Automation Platform (ONAP). As Bell's strategic partner, Amdocs brings unparalleled ONAP expertise and DevOps scrum team agility and delivery capabilities with the goal of driving innovation faster and reducing the cost of building and operating the data center of the future. With clear benefits such as a more elastic network and increased business agility to be gained from taking advantage of network functions virtualization (NFV), Bell is driving its network transformation by leveraging the ONAP-based network serv
Alvogen CEO Robert Wessman speaks exclusively to World Finance about new opportunities in generic pharmaceuticals22.1.2018 11:51 | Pressmeddelande
LONDON, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Industry disruptor Robert Wessman, the CEO of rapidly growing generic pharmaceuticals company Alvogen, shares his thoughts on the latest market trends in the new edition of World Finance magazine. Only different in name and price, generic pharmaceuticals in the US are a whopping 50 to 70 percent less expensive than their branded equivalents. Unsurprisingly, in an era of ever-rising medical costs, a growing number of governmental entities and corporations are now choosing generics over branded pharmaceuticals. For some time, just a handful of big-name organisations dominated this nascent market. But, following its peak in 2015, over-valuations have prompted vulnerability, opening the door for new, more nimble competitors to join and disrupt the market. Among this innovative group of 'next generation' pharmaceutical companies is Reykjavik-based Alvogen. Though it was only established in 2009, this global-facing organisation now boasts an annual t
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum